On the public citation graph

Criteria for deciding cost-effectiveness for expensive new anti-cancer agents

https://doi.org/10.4103/0973-1482.39685
0 signed · 35 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4650638openalex-extracted
New Compound Real Option Pricing Method with Lévy Processes for the Quality-by-Design Pharmaceutical R&D
inferred← citeshttps://doi.org/10.1002/cncr.30549openalex-snapshot
Improving access to high‐cost cancer drugs in Latin America: Much to be done
inferred← citeshttps://doi.org/10.1007/978-0-387-85900-2_3openalex-snapshot
Epidemiology of Diabetic Retinopathy
inferred← citeshttps://doi.org/10.1007/978-0-387-85900-2_4openalex-snapshot
Systemic and Ocular Factors Influencing Diabetic Retinopathy
inferred← citeshttps://doi.org/10.1007/978-1-4614-3439-9_13openalex-snapshot
Treatment of Retinal Vein Occlusions
inferred← citeshttps://doi.org/10.1007/978-3-030-01207-6_3openalex-snapshot
Oncology from an HTA and Health Economic Perspective
inferred← citeshttps://doi.org/10.1007/s00520-017-3610-2openalex-snapshot
Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria
inferred← citeshttps://doi.org/10.1007/s10269-011-2017-9openalex-snapshot
The economic pressures for biosimilar drug use in cancer medicine
inferred← citeshttps://doi.org/10.1007/s10549-012-2326-8openalex-snapshot
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s10549-017-4473-4openalex-snapshot
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives
inferred← citeshttps://doi.org/10.1007/s11523-011-0196-3openalex-snapshot
The economic pressures for biosimilar drug use in cancer medicine
inferred← citeshttps://doi.org/10.1007/s12029-016-9862-0openalex-snapshot
The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical Trials
inferred← citeshttps://doi.org/10.1016/j.clcc.2016.07.002openalex-snapshot
The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III Trials
inferred← citeshttps://doi.org/10.1016/j.clgc.2018.02.006openalex-snapshot
Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma
inferred← citeshttps://doi.org/10.1016/j.clgc.2018.11.010openalex-snapshot
Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma
inferred← citeshttps://doi.org/10.1016/j.cllc.2015.12.005openalex-snapshot
Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1016/j.eururo.2012.06.002openalex-snapshot
Robot-assisted Radical Prostatectomy – Fake Innovation or the Real Deal?
inferred← citeshttps://doi.org/10.1016/j.genhosppsych.2014.07.004openalex-snapshot
Cost effectiveness of telecare management for pain and depression in patients with cancer: results from a randomized trial
inferred← citeshttps://doi.org/10.1016/j.jcpo.2014.01.002openalex-snapshot
Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies
inferred← citeshttps://doi.org/10.1016/j.mjafi.2013.06.003openalex-snapshot
Health economics and cost-effectiveness research with special reference to hemato-oncology
inferred← citeshttps://doi.org/10.1016/s1470-2045(11)70141-3openalex-snapshot
Delivering affordable cancer care in high-income countries
inferred← citeshttps://doi.org/10.1017/s026646231000125xopenalex-snapshot
Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value
inferred← citeshttps://doi.org/10.1039/c4ra02784aopenalex-snapshot
Multifunctional pentacyclic triterpenoids as adjuvants in cancer chemotherapy: a review
inferred← citeshttps://doi.org/10.1080/14737167.2017.1259570openalex-snapshot
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations
inferred← citeshttps://doi.org/10.1080/14737167.2020.1779064openalex-snapshot
A systematic review of economic evaluations of treatment regimens in multiple myeloma
inferred← citeshttps://doi.org/10.1097/igc.0000000000001106openalex-snapshot
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer
inferred← citeshttps://doi.org/10.1111/j.1365-2753.2010.01565.xopenalex-snapshot
The application of pharmacoeconomic modelling to estimate a value‐based price for new cancer drugs
inferred← citeshttps://doi.org/10.1177/1078155210390724openalex-snapshot
A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe
inferred← citeshttps://doi.org/10.1177/1078155217727140openalex-snapshot
Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness
inferred← citeshttps://doi.org/10.1200/jco.2008.21.0534openalex-snapshot
Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
inferred← citeshttps://doi.org/10.2165/11584210-000000000-00000openalex-snapshot
Advances in Cancer Therapeutics and Patient Access to New Drugs
inferred← citeshttps://doi.org/10.2217/nnm.13.15openalex-snapshot
Assessing The Need for Quality-Adjusted Cost–Effectiveness Studies of Nanotechnological Cancer Therapies
inferred← citeshttps://doi.org/10.37506/ijphrd.v11i10.13264openalex-snapshot
An Analysis of Government Health Expenditure and Its Impact on Health of the Population in Indian States –An Empirical Study
inferred← citeshttps://doi.org/10.4018/978-1-61520-905-7.ch006openalex-snapshot
Creating a One-to-One Relationship in the Data from a Many-to-Many
inferred← citeshttps://doi.org/10.4103/0973-1482.42250openalex-snapshot
Particle therapy in clinical practice: Is there enough evidence to justify the current surge in interest?
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.